8-K: Research Alliance Corp IV Prices $75M IPO, Finalizes Indemnity Agreements

Research Alliance Corporation IV announced the pricing of its $75 million initial public offering and entered into material definitive agreements, including underwriting and indemnity agreements.

Summary

• Research Alliance Corporation IV (the Company) has priced its initial public offering (IPO) of 7,500,000 Class A ordinary shares at $10.00 per share, raising gross proceeds of $75,000,000.
• The Company also entered into several material definitive agreements in connection with the IPO, including an Underwriting Agreement, an Investment Management Trust Agreement, a Registration and Shareholder Rights Agreement, Indemnity Agreements with officers and directors, a Letter Agreement with the Sponsor and officers/directors, a Private Placement Shares Purchase Agreement, and an Indemnification Agreement with the Sponsor.
• The IPO is expected to close on July 14, 2026, with net proceeds of $75,000,000 deposited into a trust account.
• The Company is a blank check company focused on the healthcare or healthcare-related industries.
• Alan Musso and John Maslowski were appointed to the Board of Directors on July 10, 2026, and have been assigned roles on the Audit, Nominating, and Compensation Committees.
• The Sponsor purchased 275,000 Private Placement Shares at $10.00 per share, totaling $2,750,000.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development, as the successful pricing of the IPO and the establishment of critical agreements indicate progress towards the company's objective of finding a business combination.

Positives

• Successful pricing of a $75 million IPO, indicating investor confidence.
• Establishment of key agreements, including underwriting and trust agreements, to facilitate the IPO and future operations.
• Appointment of new directors with relevant committee assignments, strengthening board oversight.
• Private placement of shares to the Sponsor, providing additional capital and aligning sponsor interests.

Negatives

• The Company is a blank check company, meaning its success is contingent on finding and completing a suitable business combination.
• The IPO proceeds are held in a trust account, with access contingent on consummating a business combination within a specified timeframe (24 months).

Risks

• The Company may not be able to find a suitable business combination target within the specified timeframe, leading to liquidation.
• The success of the Company is dependent on the expertise of its management team in identifying and executing a business combination in the healthcare sector.
• Indemnity agreements expose the Company to potential future liabilities related to claims against its officers and directors.
• The Private Placement Shares are subject to transfer restrictions until 30 days after the completion of the Company's initial business combination.

Future Outlook

The Company is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination. It intends to focus its search on a target business in the healthcare or healthcare-related industries. The IPO proceeds are held in a trust account and will be used to fund a business combination. If a business combination is not consummated within 24 months of the IPO closing, the Company will liquidate.

Management Comments

• Research Alliance Corporation IV (the Company), a special purpose acquisition company, announced today the pricing of its initial public offering of 7,500,000 Class A ordinary shares at $10.00 per share.
• The Company may pursue an initial business combination in any business, industry, sector or geographical location, but the Company intends to focus its search on a target business in the healthcare or healthcare-related industries, where it believes the expertise of its management team will provide it with a competitive advantage in completing a successful initial business combination.

Industry Context

StockSavvy.ai notes that the formation and IPO of a Special Purpose Acquisition Company (SPAC) like Research Alliance Corporation IV is a common strategy for investors to gain exposure to specific sectors, in this case, healthcare, without directly investing in private companies. The success of such entities hinges on the management team's ability to identify and execute a favorable business combination within a defined timeframe.

Comparison to Industry Standards

• The IPO pricing of $10.00 per share is a standard benchmark for many SPAC IPOs, aiming to provide a stable entry point for investors.
• The 24-month timeframe for completing a business combination is typical for SPACs, aligning with regulatory expectations and investor timelines.
• The focus on the healthcare industry is a strategic choice, reflecting current market trends where specialized SPACs often target sectors with perceived growth potential and where management has demonstrated expertise.

Management Changes

Corporate Governance

Related Party Transactions

• The Sponsor, Research Alliance Holdings IV LLC, purchased 275,000 Class A ordinary shares (Private Placement Shares) at $10.00 per share for a total of $2,750,000.
• The Sponsor and executive officers/directors have agreed to vote their shares in favor of the Company's initial business combination.
• The Sponsor has certain indemnification obligations to the Company.
• The Company has agreed not to enter into a definitive agreement for an initial business combination without the Sponsor's prior consent.
• The Company entered into an Indemnification Agreement with the Sponsor, agreeing to indemnify the Sponsor and its affiliates from certain liabilities.

Stakeholder Impact

• Shareholders: Public shareholders now have a stake in a publicly traded SPAC with the potential for future growth through a business combination. They are subject to the risks associated with SPACs and the healthcare industry.
• Sponsor: The Sponsor has secured its investment through private placement shares and has significant influence over the business combination process, while also being subject to indemnification obligations and transfer restrictions.
• Officers and Directors: They are provided with indemnification against certain claims arising from their service, encouraging them to serve, but are also subject to specific voting and transfer restrictions.
• Trustee (Continental Stock Transfer & Trust Company): Has responsibilities related to managing the IPO proceeds in the trust account and is indemnified by the Company.

Next Steps

• The Company will use the net proceeds from the IPO and private placement to fund a business combination.
• The Company has 24 months from the IPO closing to complete a business combination, or it will liquidate.
• The Company will file an audited balance sheet reflecting IPO and private placement proceeds within 4 business days of IPO consummation.

Key Dates

Keywords

Special Purpose Acquisition Company, SPAC, IPO, Research Alliance Corporation IV, Healthcare, Indemnity Agreement, Trust Account, Class A Ordinary Shares